ROCKVILLE, Md., March 11,
2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)
today announced it will participate the following upcoming investor
conferences:
Leerink Partners 2024 Global Biopharma
Conference
Date: Tuesday,
March 12, 2024
Location: Miami, FL
1x1 investor meetings only
Barclays 26th Annual Global Healthcare
Conference
Fireside Chat: Wednesday, March 13, 2024 at 4:05 p.m. ET
Gene Therapy Regulatory Path in Rare Diseases Panel:
Wednesday, March 13, 2024 at
4:35 p.m. ET
Location: Miami, FL
UBS Virtual CNS Day
Fireside Chat: Monday,
March 18, 2024 at 3:30 p.m. ET
Location: Virtual
A live webcast of the fireside chat at the Barclays conference
can be accessed in the Investors section of REGENXBIO's website at
www.regenxbio.com. An archived replay of the webcast will be
available for approximately 30 days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. Since its founding in 2009, REGENXBIO has pioneered the
development of AAV Therapeutics, an innovative class of gene
therapy medicines. REGENXBIO is advancing a pipeline of AAV
Therapeutics for retinal and rare diseases, including ABBV-RGX-314
for the treatment of wet AMD and diabetic retinopathy, being
developed in collaboration with AbbVie, RGX-202 for the treatment
of Duchenne and RGX-121 for the treatment of MPS II. Thousands of
patients have been treated with REGENXBIO's AAV Therapeutic
platform, including Novartis' ZOLGENSMA for children with spinal
muscular atrophy. Designed to be one-time treatments, AAV
Therapeutics have the potential to change the way healthcare is
delivered for millions of people. For more information, please
visit www.regenxbio.com.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302084950.html
SOURCE REGENXBIO Inc.